<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160110025937N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-16</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of using a reminder application and medication reminder box on the adherence of patients with heart failure to the medication regimen</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of using a reminder application and medication reminder box on the adherence of patients with heart failure to the medication regimen: a randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-08-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>189</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53606</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, based on the inclusion criteria of heart failure patients from the Cardiovascular Clinic of Shahid Madani Hospital in Tabriz in 1400 will be selected by available methods and by stating the objectives of the research, their consent and consent will be obtained to participate in the study. Participants in the study randomly using RAS software with blocks of sizes 6 and 9 and 1: 1: 1 allocation ratio in three control groups and the first intervention group (drug reminder box) and the second intervention group (web SMS reminder system) ) will be placed. To hide the allocation, opaque, closed and identical envelopes will be used and the envelopes will be numbered from 1 to 189 and the type of intervention will be written on paper based on a random allocation sequence and placed inside the envelopes, respectively. Production of the allocation sequence and preparation of the envelopes based on it will be done by a person not involved in the research. In order to control age as a confounding factor, stratification will be done in terms of age. According to the proportion of patients with heart failure aged 18-45 years and 46 years and above, one-fifth of the envelopes will be allocated to the first age group and the rest to the second age group, Blinding description: This study is a single-blind controlled trial that includes the control group (no intervention) and the first intervention group (receiving a medicine box) and the second intervention group (receiving a reminder SMS). In this intervention, to prevent possible bias in the study results, all samples will be examined by a cardiologist who is not aware of how the samples are placed in the intervention and control groups, and their cardiac function status is based on the performance status classification scale. The New York Heart (NYHA) will be examined at the beginning of the study. Also, data related to adherence to the drug regimen will be collected by a researcher who is not aware of how the samples are placed in the intervention and control groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Heart failure.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: patients of the first intervention group 4 medicine boxes for storing medicines for one month, each of which is the medicine needed for a week in the morning, noon, evening and night meals prepared by the researcher for the group participants. The first intervention is prepared to receive. Then drugs for heart failure in 5 classes of drugs (diuretics, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, beta-blockers and digital) will be placed in medicine boxes for 4 weeks by the researcher. The first intervention group will then be instructed on how to use the medicine box and then will be given feedback on the ability to use the device in practice. Participants will use this device for 3 months. The researcher will also be provided with the researcher's phone number to contact him or her if needed. At the end of 4 weeks, the researcher will contact the participant and ask the participants to count the amount of pills left by the researcher and place the pills for the second month, as well as to complete the medication compliance questionnaire and the checklist of cognitive levels. Record the use of drugs by the researcher to go to the clinic again and the amount of drug compliance will be calculated by dividing the amount of pills received according to the form completed by patients and counting the remaining pills by the researcher to the number of pills prescribed for all groups. The same will be done for the second and third months. Intervention 2: Second intervention group: management and SMS sending software was designed for the patients of the second intervention group. This software is specially implemented for managing SMS recipients with the possibility of sending SMS in groups or individually. In setting the content of the SMS for the recipients, using the combination of the details of the recipient of the SMS, including the name and the selected text, makes the recipient familiar with the main content of the SMS. Basic information management is done in the form of contact information management, contact grouping, determining the specific and general text of the SMS in this software. After preparing the text of the text messages and the desired settings, the text messages are sent on the telecommunication platform through a dedicated modem that can use the telecommunication SIM card. The possibility of using panels and web telecommunication services to send text messages is also provided in this software. In this group, during the meeting, arranged on how to use SMS, which can be managed by this web-based software with the ability to manage patients' identity cards and medication regimens, and the possibility of sending the desired information at specified intervals to the SMS system. The Internet will be trained to send personalized SMS reminders that will be sent to patients several times a day at specific times according to the medication regimen, and feedback will be practically taken from the learning. And the drugs prescribed by the doctor, which should be taken by patients in this group within a month, will be poured into a can, and at the end of 30 days, the researcher will contact the participant and ask the participants to count the number of pills. Remaining by the researcher and completing the MARS Medication Adherence Questionnaire and the Cognitive Level Status Questionnaire and the Checklist for Registering Drug Use by the researcher and placing the next month's pills in the box, return to the clinic. You will also be asked questions and notes during a telephone call to the hospital during the past month due to this illness or other causes. The researcher's phone number will be provided to the participants to contact the researcher if they need help. The same will be done for the second and third months. It should be noted that all the outcomes in the mentioned times in hospitalized patients will be examined and the analysis will be done in groups with and without considering them and in case of differences in the significance of both results will be reported. Meanwhile, the length of each text message and the number of words are short and the messages will be understandable and simple for the participants, and the text messages sent in standard format will be received and used by all phones that can be used in the country's mobile network. The text of the SMS will be as follows: Mr. / Madam ---- Please take the medicine ---- in a dose of ---- at ---- hour. Finally, at the end of each intervention month, the degree of adherence to the medication regimen in this group will be determined by filling out an MARS Medication Adherence Questionnaire. Intervention 3: Control group: the control group of drugs prescribed by a doctor that should be taken by patients in this group during a month will be placed in a can by the researcher and at the end of each month the participants in this group will be contacted and asked. To count the number of remaining pills in each drug group and to complete the Drug Adherence Questionnaire and the Cognitive Level Status Questionnaire and the Drug Registration Checklist and to put the pills in the box next month, go to the clinic again and so on for the second and third months. Will be acted upon.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Requested data will be provided to researchers for statistical analysis of the submitted proposal (meta-analysis).

When:
starting access immediately after publication

To whom:
Data will be available to researchers as well as to journals.

Conditions:
The data will be available to researchers upon request and submission of a proposal to perform meta-analysis using IPD data after being unidentified. Also, in exceptional cases, data will be made available to journals for checking.

Where to obtain:
Refer to the email address (allahbakhshiana@tbzmed.ac.ir).

How to obtain:
The requests will be sent by email and data will be available within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Atefeh Allahbakhshian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz School of Nursing and Midwifery, Southern Shariati St., Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3479 6770</telephone>
        <email>allahbakhshiana@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Atefeh Allahbakhshian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tabriz School of Nursing and Midwifery, Southern Shariati St., Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3479 6770</telephone>
        <email>allahbakhshiana@tbzmedn.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Minimum age 18 years
Ability to read and write in Persian
Early diagnosis of chronic heart failure confirmed by a cardiologist
No cognitive problems based on the Cognitive Level Status Questionnaire ATMS (Abbreviated Mental Test Score)
Mobile phone availability and ability to use it
Class 2 and 3 heart failure based on the New York Cardiac Function Scale for 3 months or more based on the physician</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having cognitive impairment
Inability to read short messages
Lack of access to mobile phones</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Heart failure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: patients of the first intervention group 4 medicine boxes for storing medicines for one month, each of which is the medicine needed for a week in the morning, noon, evening and night meals prepared by the researcher for the group participants. The first intervention is prepared to receive. Then drugs for heart failure in 5 classes of drugs (diuretics, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, beta-blockers and digital) will be placed in medicine boxes for 4 weeks by the researcher. The first intervention group will then be instructed on how to use the medicine box and then will be given feedback on the ability to use the device in practice. Participants will use this device for 3 months. The researcher will also be provided with the researcher's phone number to contact him or her if needed. At the end of 4 weeks, the researcher will contact the participant and ask the participants to count the amount of pills left by the researcher and place the pills for the second month, as well as to complete the medication compliance questionnaire and the checklist of cognitive levels. Record the use of drugs by the researcher to go to the clinic again and the amount of drug compliance will be calculated by dividing the amount of pills received according to the form completed by patients and counting the remaining pills by the researcher to the number of pills prescribed for all groups. The same will be done for the second and third months.</i_keyword>
      <i_keyword>Second intervention group: management and SMS sending software was designed for the patients of the second intervention group. This software is specially implemented for managing SMS recipients with the possibility of sending SMS in groups or individually. In setting the content of the SMS for the recipients, using the combination of the details of the recipient of the SMS, including the name and the selected text, makes the recipient familiar with the main content of the SMS. Basic information management is done in the form of contact information management, contact grouping, determining the specific and general text of the SMS in this software. After preparing the text of the text messages and the desired settings, the text messages are sent on the telecommunication platform through a dedicated modem that can use the telecommunication SIM card. The possibility of using panels and web telecommunication services to send text messages is also provided in this software. In this group, during the meeting, arranged on how to use SMS, which can be managed by this web-based software with the ability to manage patients' identity cards and medication regimens, and the possibility of sending the desired information at specified intervals to the SMS system. The Internet will be trained to send personalized SMS reminders that will be sent to patients several times a day at specific times according to the medication regimen, and feedback will be practically taken from the learning. And the drugs prescribed by the doctor, which should be taken by patients in this group within a month, will be poured into a can, and at the end of 30 days, the researcher will contact the participant and ask the participants to count the number of pills. Remaining by the researcher and completing the MARS Medication Adherence Questionnaire and the Cognitive Level Status Questionnaire and the Checklist for Registering Drug Use by the researcher and placing the next month's pills in the box, return to the clinic. You will also be asked questions and notes during a telephone call to the hospital during the past month due to this illness or other causes. The researcher's phone number will be provided to the participants to contact the researcher if they need help. The same will be done for the second and third months. It should be noted that all the outcomes in the mentioned times in hospitalized patients will be examined and the analysis will be done in groups with and without considering them and in case of differences in the significance of both results will be reported. Meanwhile, the length of each text message and the number of words are short and the messages will be understandable and simple for the participants, and the text messages sent in standard format will be received and used by all phones that can be used in the country's mobile network. The text of the SMS will be as follows: Mr. / Madam ---- Please take the medicine ---- in a dose of ---- at ---- hour. Finally, at the end of each intervention month, the degree of adherence to the medication regimen in this group will be determined by filling out an MARS Medication Adherence Questionnaire.</i_keyword>
      <i_keyword>Control group: the control group of drugs prescribed by a doctor that should be taken by patients in this group during a month will be placed in a can by the researcher and at the end of each month the participants in this group will be contacted and asked. To count the number of remaining pills in each drug group and to complete the Drug Adherence Questionnaire and the Cognitive Level Status Questionnaire and the Drug Registration Checklist and to put the pills in the box next month, go to the clinic again and so on for the second and third months. Will be acted upon.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Medication Adherence. Timepoint: Before the intervention, at the end of the first, second and third months after the intervention. Method of measurement: Medication Adherence Rating Scale Questionnaire and use the medicine box.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Hospitalization. Timepoint: After the end of the intervention. Method of measurement: Self-report of patients.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-12</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>3rd floor, Central Building No. 2, Tabriz University of Medical Sciences, Golgasht St. Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
